These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 28051801

  • 1. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
    Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, Wang X, Wang JF, Lu W, Li CZ, Mao Y, Wang GQ, Gao YQ, Wang B, Zhang Q, Ge Y, Wong VW.
    Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
    [Abstract] [Full Text] [Related]

  • 2. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG.
    BMC Gastroenterol; 2018 Sep 04; 18(1):137. PubMed ID: 30180806
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG.
    World J Gastroenterol; 2014 Aug 28; 20(32):11400-5. PubMed ID: 25170228
    [Abstract] [Full Text] [Related]

  • 4. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H.
    Intern Med; 2018 Sep 01; 57(17):2451-2458. PubMed ID: 29607963
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 01; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 6. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
    Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.
    Intern Med; 2017 Nov 15; 56(22):2993-3001. PubMed ID: 28943585
    [Abstract] [Full Text] [Related]

  • 7. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.
    J Hepatol; 2012 Mar 15; 56(3):571-8. PubMed ID: 22027579
    [Abstract] [Full Text] [Related]

  • 8. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators.
    N Engl J Med; 2006 Nov 16; 355(20):2099-112. PubMed ID: 17105757
    [Abstract] [Full Text] [Related]

  • 9. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 16; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 10. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L, Bai H, Zhu WL, Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct 16; 39(10):936-40. PubMed ID: 22321279
    [Abstract] [Full Text] [Related]

  • 11. Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: Report on safety and effectiveness.
    Liu YH, Han XB, Fei YH, Xu HT.
    Medicine (Baltimore); 2017 Dec 16; 96(52):e9539. PubMed ID: 29384972
    [Abstract] [Full Text] [Related]

  • 12. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW, Yi JH, Kang KP, Kim HY, Kim SW, Choi HY, Ha SK, Kim GH, Kim YW, Jeong KH, Shin SK, Kim HJ.
    J Korean Med Sci; 2018 Apr 09; 33(15):e112. PubMed ID: 29629516
    [Abstract] [Full Text] [Related]

  • 13. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience.
    Pose E, Solà E, Piano S, Gola E, Graupera I, Guevara M, Cárdenas A, Angeli P, Ginès P.
    Am J Med; 2017 Mar 09; 130(3):372-375. PubMed ID: 27746291
    [Abstract] [Full Text] [Related]

  • 14. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 09; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 15. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S, Aydın Kaderli A, Yıldız A, Gül BC, Özdemir B, Baran İ, Güllülü S, Aydınlar A, Çavuşoğlu Y.
    Turk Kardiyol Dern Ars; 2017 Jul 09; 45(5):415-425. PubMed ID: 28694395
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Oral Tolvaptan Therapy in Hospitalized Cirrhotic Patients with Hyponatremia.
    Garg R, Kaur K, Aggarwal S, Singh N.
    J Assoc Physicians India; 2018 Dec 09; 66(12):49-52. PubMed ID: 31315326
    [Abstract] [Full Text] [Related]

  • 17. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 09; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 18. Utility of Tolvaptan in the Perioperative Management of Severe Hyponatremia During Liver Transplantation: A Case Report.
    Parekh A, Rajaram P, Patel G, Subramanian RM.
    Transplant Proc; 2017 Dec 09; 49(10):2399-2401. PubMed ID: 29198689
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C, Lesch C, Berger K.
    Pharmacotherapy; 2017 May 09; 37(5):528-534. PubMed ID: 28295447
    [Abstract] [Full Text] [Related]

  • 20. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I.
    Expert Rev Gastroenterol Hepatol; 2014 Jul 09; 8(5):461-70. PubMed ID: 24678622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.